In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PTC gets two rare disease therapies from Akcea

Executive Summary

Ionis Pharmaceuticals Inc.’s Akcea Therapeutics Inc. licensed PTC Therapeutics Inc. exclusive rights to develop, manufacture, and commercialize its rare disease drugs Tegsedi (inotersen) and Waylivra (volanesorsen) in Latin America and certain Caribbean countries. Akcea has also granted PTC a right of first negotiation to commercialize AKCEA-TTR-LRx, a follow-on candidate to inotersen, on an exclusive basis in the territories.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies